Lyra Therapeutics, Inc.LYRANASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank42
Year-over-Year Change
Year-over-year free cash flow growth rate
Percentile
P42
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -11.36% |
| Q2 2025 | 25.24% |
| Q1 2025 | 21.71% |
| Q4 2024 | 30.60% |
| Q3 2024 | 19.34% |
| Q2 2024 | 17.99% |
| Q1 2024 | -23.98% |
| Q4 2023 | -39.19% |
| Q3 2023 | 0.66% |
| Q2 2023 | 9.70% |
| Q1 2023 | -30.37% |
| Q4 2022 | -12.11% |
| Q3 2022 | -28.18% |
| Q2 2022 | 29.29% |
| Q1 2022 | 3.09% |
| Q4 2021 | -14.30% |
| Q3 2021 | -493.00% |
| Q2 2021 | 131.50% |
| Q1 2021 | -25.56% |
| Q4 2020 | -59.51% |
| Q3 2020 | 42.17% |
| Q2 2020 | -87.70% |
| Q1 2020 | -0.68% |
| Q4 2019 | -4.20% |
| Q3 2019 | -24.86% |
| Q2 2019 | -0.52% |
| Q1 2019 | 0.00% |